Iceland based pharmaceutical company Actavis Group announced on Wednesday that it had doubled its year-on-year revenue, which was EUR 1,379 million (USD 1.8 billion) last year.
According to Morgunbladid, Actavis Group’s overall profit in 2006 was EUR 103 million (USD 136 million). Actavis CEO Róbert Wessman is reportedly very pleased with the results and said ambitious goals had been achieved.
Actavis invested in four new companies in 2006, focusing primarily on eastern Europe and the US. Last year the sale of medicine increased in those two markets by 12 to 18 percent.
